A Phase II proof of concept study has shown that one of Argenx’ antibodies is effective in treating the neuromuscular disease myasthenia gravis.
Argenx has released the results from a Phase II trial with ARGX-113 (efgartigimod), in which the antibody therapy has proved to provide a significant improvement in patients with generalized myasthenia gravis, a form of the disease that affects the strength of multiple muscles simultaneously. Argenx’ stock on Euronext Brussels is up by 24% a few hours after it opened this